Paul Sondel, MD

Paul Sondel, MD

Pediatric Hematology & Oncology Madison, WI

Professor of Pediatrics, University Wisc


Office Address

  • 600 Highland Ave
    Madison, WI 53792
    Phone: (608) 263-6420
    Fax: (608) 263-0440

Are you Dr. Sondel?

Claim your profile and join over 50% of U.S. physicians already on Doximity.

Claim this pageNo, this isn't me

Paul Sondel, MD

Pediatric Hematology & Oncology Madison, WI

Professor of Pediatrics, University Wisc

36 Colleague InvitesIs this you? Register Now to see 36 messages.

Summary

  • Dr. Paul Sondel, MD is a board certified pediatric hematologist/oncologist in Madison, Wisconsin. He is currently licensed to practice medicine in Wisconsin. He is affiliated with Meriter Hospital and University of Wisconsin Hospital and Clinics.

Clinical Specialties & Interests

  • Pediatric Hematology & Oncology: General Pediatric Hematology & Oncology

Education & Medical Training

  • Harvard Medical SchoolHarvard Medical School
  • University of Minnesota at FairviewUniversity of Minnesota at Fairview
  • University of WisconsinUniversity of Wisconsin

Certifications & Licensure

  • WI State Medical LicenseWI State Medical License1978 - 2015
  • American Board of PediatricsPediatrics

Awards, Honors, & Recognition

  • America's Top DoctorsCastle Connolly, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2003, 2002
  • America's Top Doctors for CancerCastle Connolly, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005
  • Elected MemberThe American Society for Clinical Investigation, 1988

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • The Role Of KIR And Fcr Genotype In The Efficacy Of MAB And IL2 ImmunotherapyNational Cancer Institute
    2012 - 2012
  • Antitumor Mechanisms Of Anti-Cd40/Cpg-Activated MacrophagesNational Cancer Institute
    2008 - 2011
  • Phase I Study Of Fenretinide LXS Oral Powder In Patients With NeuroblastomaNational Center For Research Resources
    2007 - 2007
  • 131I-MIBG With Intensive Chemotherapy And Autologous Stem Cell RescueNational Center For Research Resources
    2006 - 2007
  • Clinical Development Of Hu14.18-Il2 Targeted TherapyNational Cancer Institute
    2006 - 2011
  • Phase II Trial Of Hu1418-Il2 (Emd 273063) In Subjects With Advanced MelanomaNational Center For Research Resources
    2006 - 2007
  • Phase I Trial Of Hu14.18-Il-2 In Neuroblastoma And Other Gd2+ TumorsNational Center For Research Resources
    2004 - 2004
  • T-Cell Independent Antitumor Mechanisms Of CD40 LigationNational Cancer Institute
    2002 - 2005
  • Clinical Development Of Hu14.18 IL2 Targeted TherapyNational Cancer Institute
    2000 - 2004
  • Phase I Study Of Taxol In Refractory Leukemia In ChildrenNational Center For Research Resources
    1999 - 2002
  • Maintenance Treatment Of Therapy Refractory All W/ B43 PAP ImmunotoxiNational Center For Research Resources
    1999 - 2002
  • Antibody IL-2 Fusion Protein Delivery By Gene TransferNational Cancer Institute
    1996 - 1998
  • Clinical Testing Of Ch1418-Il2 For Gd2+ TumorsNational Cancer Institute
    1996 - 1998
  • Systemic Immunity By Particle Mediated BRM Gene TransferNational Cancer Institute
    1996 - 1999
  • Phase I Trial Of Melanoma Reactive Ch.14.18 PLUS IL2 In Adults With MelanomaNational Center For Research Resources
    1995 - 1996
  • In Vitro Reactivity And Regulation Of Lymphocyte Response In LymphocytesNational Center For Research Resources
    1995 - 1995
  • Combined Modality Antibody Directed Cell CytotoxicityNational Cancer Institute
    1995 - 1995
  • Immunobiology Of Antileukemic LymphocytesNational Cancer Institute
    1994 - 1994
  • Combined Modality Antibody-Directed Cell CytotoxicityNational Cancer Institute
    1993 - 1995
  • Antitumor Artificial Receptors As Cancer VaccinesNational Cancer Institute
    1992 - 1995
  • BRM Monitoring Of Pediatric Neuroblastoma/OsteosarcomaNational Cancer Institute
    1990 - 1991
  • Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute
    1990 - 1993
  • Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment
    1990 - 1994
  • Autologous LAK Cells &Il-2 In Cancer PatientsDivision Of Cancer Treatment
    1987 - 1990
  • Clinical Trial Of Natural And Recombinent Interleukin-2Division Of Cancer Treatment
    1986 - 1986
  • The Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute
    1985 - 1989
  • Core--Scintillation Counting ServicesNational Cancer Institute
    1985 - 1985

Professional Memberships

Hospital Affiliations

Alternate Names

  • Dr. Paul Sondel, Dr. Paul Sondel, MD, Dr. P Sondel, Dr. Paul M Sondel

Physicians, view Dr. Sondel's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV

© 2015 Doximity, Inc.GroupsHelpBlogCompanyContactPrivacyDirectory